Could efficacy at 1week after galcanezumab administration for patients with migraine predict responders at 3months? A real world study.

Abstract

In real-world studies, it is unclear whether galcanezumab has a significant effect in the first week after administration. We retrospectively assessed 55 high-frequency episodic migraine (HFEM) and chronic migraine patients who received three galcanezumab doses. Mean changes in the numbers of weekly migraine days (WMDs) during month 1 and migraine days per month (MMDs) after 1-3months of treatment were obtained. Clinical factors related to a ≥ 50% response rate (RR) at month 3 were analyzed. The prediction of ≥ 50% responders at month 3 using different weekly RRs at week 1 (W1) was evaluated. The RR at W1 was calculated with the following formula: RR (%) = 100 - [(WMDs at W1/baseline WMD) × 100]. The number of MMDs significantly improved from baseline to 1, 2 and 3months. The ≥ 50% RR was 50.9% at 3months. The number of WMDs decreased significantly from baseline to week 1 (- 1.6 ± 1.7days), week 2 (- 1.2 ± 1.6days), week 3 (- 1.0 ± 1.3days), and week 4 (- 1.1 ± 1.6days) during month 1. The RR at W1 was largest (44.6 ± 42.2%). The ≥ 30%, ≥ 50% and ≥ 75% RRs at W1 were significantly predictive of a ≥ 50% RR at 3months. Logistic regression analysis predicting a ≥ 50% RR at month 3 showed that the RR at W1 was the sole contributing factor. In our study, galcanezumab showed a significant effect in the first week after administration, and the RR at W1 could predict the RR at 3months.